About US
Contact us
-
EC grants approval for Bristol-Myers' Opdivo to treat renal cell carcinomaBristol-Myers Squibb has obtained approval from the European Commission (EC) for its Opdivo (nivolumab) for previously treated advanced renal cell carcinoma (RCC). RCC is the most common type of kidn2016/5/20
-
Gilead's Descovy receives FDA approval to treat HIVAmerican biopharmaceutical company Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for Descovy (emtricitabine 200mg/tenofovir alafenamide 25mg, F/TAF) to treat pati2016/5/19
-
EMA committee recommends approval of Amicus' Galafold to treat Fabry diseaseThe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a marketing authorisation of Amicus Therapeutics' Galafold (migalastat) to treat Fabry disea2016/5/18
-
Leo Pharma wins approval to use Enstilar for psoriasis vulgaris treatment in EULeo Pharma has received scientific approval for Enstilar for treatment of psoriasis vulgaris in the EU. Psoriasis is a chronic, inflammatory skin disease, which is frequently accompanied by multiple2016/5/17
-
Deals of the week: Daiichi Sankyo, Trianni, AptinyxDaiichi Sankyohas entered an agreement with Nitto Denko to use the latter's proprietary PassPort active transdermal drug delivery technology, for the development of an undisclosed product of the forme2016/5/16
-
FDA grants Orphan Drug Designation to AstraZeneca’s selumetinib for thyroid cancerThe US Food and Drug Administration (FDA) has granted Orphan Drug Designation to AstraZeneca's investigational MEK 1/2 inhibitor, selumetinib (AZD6244, ARRY-142886), to treat patients with stage III o2016/5/16
-
M&As this week: Sygnis, Incyte, AptuitBiotechnology companySygnis AGplans to acquire proteomics company Expedeon to expand its product portfolio and develop sales in the US and European markets. The company has announced its plans to rai2016/5/13
-
Report: Heart failure market to witness a compound annual growth rate of 13.7%The heart failure market is set to grow to $11.8bn by 2025 from $3.2bn in 2015, at a compound annual growth rate of 13.7%, according to a report by GlobalData. According to the report, titled 'Pharma2016/5/13
-
LDC, Boehringer and Max Planck partner to discover treatment of SchizophreniaGerman companies Lead Discovery Centre (LDC), Boehringer Ingelheim International and Max Planck Innovation have signed an agreement to provide Boehringer with the option to receive exclusive rights to2016/5/12
-
NICE approves GSK's lupus drug BenlystaThe National Institute for Health and Care Excellence (NICE) has reportedly approved GlaxoSmithKline's (GSK) Benlysta for the treatment of lupus. Earlier in 2011, NICE rejected Benlysta as it believe2016/5/12